MMR Vaccine (Measles, Mumps and Rubella Vaccine)

The MMR vaccine gives protection against three serious diseases: measles, mumps, and rubella.

According to the World Health Organization in 2023 an estimated 107,500 people died globally from measles – mostly children under the age of five years. As well as death, measles can also cause serious complications, such as pneumonia and encephalitis - inflammation of the brain.

In the UK, as in Europe, cases of measles have been rising over the past few years. According to the UK Health Security Agency (UKHSA), during 2024, there were almost 3,000 laboratory confirmed cases of measles, compared with just 54 cases in the whole of 2022.  

And between January 2025 and the end of June 2025, there were 529 laboratory confirmed cases. Some 44% of these were in London, with 32% of cases in young children, aged one to four, and 22% in children aged five to 10 years old.

The rise is mainly down to a fall in the number of children being vaccinated. 

Mumps can also lead to serious complications, such as meningitis and encephalitis. Rubella can be very dangerous for pregnant women, causing miscarriage or serious abnormalities in the unborn baby.

Children get two doses of the MMR vaccine. The first dose is given at 12-13 months in the UK schedule. Currently a booster dose is given at 3 years and 4 months at the same time as the preschool booster.

From January 2026 children will get their second dose at 18 months instead. This change affects children born since July 2024, who will get the earlier 18-month dose. It is hoped this change will increase the number of children fully vaccinated with the MMR.   

The vaccine works very well. Two doses are 96% effective against measles, around 86% effective against mumps, and 89% effective against rubella.

Before the introduction of vaccines, all three diseases were extremely common; most people had them at some point, usually as children. Although many people survived without long-term effects, others were left with serious disabilities and some children died.

There is no link between the MMR vaccine and autism. Despite widespread misinformation, multiple studies have shown that there is no link between the MMR vaccine and autism, and previous studies that did report a link have been discredited. See 'more information about the vaccine' below. 

The aim of the MMR programme is to provide two doses of MMR vaccine at appropriate intervals for all eligible individuals.

Children should receive their first dose between 12 and 13 months of age, with a second dose given at 3 years and 4 months of age.

If the first dose is given before 12 months of age, either because of travel to a high-risk country or because of a local outbreak, then this dose should be ignored, and two further doses given at the recommended times. This is because the protection from the vaccine given before the recommended time may be lower than if it was given at the recommended time.

The MMR vaccine can be given after six months of age and should be offered to partially or unvaccinated individuals when the opportunity arises, for example, before starting university.

If you were born or lived outside of the UK at a young age, you may need 2 doses of MMR. Different countries offer different vaccines and not all use the combined MMR vaccine.

It is also important for healthcare workers to ensure they have full protection to ensure they do not spread disease to vulnerable people. It is also essential for individuals who travel to high-risk countries to ensure they are fully protected.

The vaccine should not be given to:

• those who are immunosuppressed
• those who have had a confirmed anaphylactic reaction to a previous dose of a measles, mumps, or rubella-containing vaccine
• those who have had a confirmed anaphylactic reaction to neomycin or gelatine
• pregnant people, as a precaution. 

Apart from the active ingredients (the antigens), both MMR vaccines may contain very small amounts of these ingredients:

• sorbitol or mannitol, used as stabilisers
• polysorbate 80, used as an emulsifier to hold other ingredients together.

M-M-RVaxPRO also contains:

• highly purified gelatine, derived from pigs, used as a stabiliser
• recombinant human serum albumin, used as a stabiliser.

The vaccine may also contain traces of these products used during the manufacturing process:

• neomycin, an antibiotic used to stop bacteria from growing and contaminating the vaccine

Growing the active ingredients for the vaccine:

• The rubella strain for both MMR vaccines is grown in the laboratory using a human cell line

The measles and mumps virus strains for both MMR vaccines are grown using a chick embryo cell (see more information about the use of animal cell lines to grow viruses for vaccines).

The viruses are not grown on eggs. This means that there is not enough egg protein in the MMR vaccine to cause allergic reactions, so children with severe egg allergies can safely receive the MMR.

Only the M-M-RVaxPRO vaccine contains gelatine. If you prefer to receive a vaccine not containing gelatine, then ask your GP for the Priorix vaccine instead

In the short film below, experts talk about measles and its complications, and the importance of the MMR vaccine.

A life changed by measles: Sarah Clow's story

Sarah Clow fell seriously ill with measles when she was five and was left with lasting disabilities including deafness, partial sight and learning difficulties. Her mother Audrey talks about the impact this has had on Sarah and the whole family. Thanks to Rockhopper TV for the original footage.

Sarah was not vaccinated against measles as a child because she had had eczema. Advice on this has now changed; current advice is that children with eczema can safely receive the MMR vaccine and other vaccines.

SSPE - a serious complication of measles: Sarah Walton's story

Sarah Walton caught measles when she was 11 months old, and at the time recovered well. Twenty four years later, however, she fell ill and was diagnosed with subacute sclerosing panencephalitis (SSPE). SSPE is a persistent viral infection, a rare but devastating complication of measles which leads to a progressive destruction of the central nervous system. It causes dementia, loss of motor control, epilepsy and eventually death. In this video Sarah’s mother Jo talks about the impact that SSPE has had on Sarah and the people around her.

For more information about the egg allergy issues raised in the video, see the 'Ingredients' section above.

 In this short film, Ian Capon talks about his experience of CRS, and advises women planning a family to check their rubella immunisation status.